Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)

ClinicalTrials.gov ID: NCT01964352

Public ClinicalTrials.gov record NCT01964352. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objective of this study is to assess the efficacy and safety of 12 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the Respimat inhaler) compared with tiotropium and placebo in patients with COPD.

Study identification

NCT ID
NCT01964352
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
813 participants

Conditions and interventions

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2013
Primary completion
Sep 30, 2014
Completion
Oct 31, 2014
Last update posted
Nov 24, 2015

2013 – 2014

United States locations

U.S. sites
20
U.S. states
11
U.S. cities
20
Facility City State ZIP Site status
1237.25.10504 Boehringer Ingelheim Investigational Site Wheat Ridge Colorado
1237.25.10507 Boehringer Ingelheim Investigational Site Clearwater Florida
1237.25.10517 Boehringer Ingelheim Investigational Site Panama City Florida
1237.25.10505 Boehringer Ingelheim Investigational Site Coeur d'Alene Idaho
1237.25.10516 Boehringer Ingelheim Investigational Site Ann Arbor Michigan
1237.25.10509 Boehringer Ingelheim Investigational Site Livonia Michigan
1237.25.10519 Boehringer Ingelheim Investigational Site Charlotte North Carolina
1237.25.10503 Boehringer Ingelheim Investigational Site Cincinnati Ohio
1237.25.10518 Boehringer Ingelheim Investigational Site Columbia Ohio
1237.25.10502 Boehringer Ingelheim Investigational Site Columbus Ohio
1237.25.10511 Boehringer Ingelheim Investigational Site Dublin Ohio
1237.25.10514 Boehringer Ingelheim Investigational Site Philadelphia Pennsylvania
1237.25.10513 Boehringer Ingelheim Investigational Site Charleston South Carolina
1237.25.10515 Boehringer Ingelheim Investigational Site Easley South Carolina
1237.25.10506 Boehringer Ingelheim Investigational Site Greenville South Carolina
1237.25.10501 Boehringer Ingelheim Investigational Site Rock Hill South Carolina
1237.25.10508 Boehringer Ingelheim Investigational Site Spartanburg South Carolina
1237.25.10520 Boehringer Ingelheim Investigational Site Killeen Texas
1237.25.10510 Boehringer Ingelheim Investigational Site Richmond Virginia
1237.25.10521 Boehringer Ingelheim Investigational Site Spokane Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 57 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01964352, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 24, 2015 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01964352 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →